Rein Therapeutics Insider Buying Surge Signals Confidence Amid Volatility and Uncertain Pipeline
Insider buying spikes at Rein Therapeutics—investors weigh insider confidence against negative P/E, flat revenue, and high volatility amid Phase II trials and regulatory milestones.
4 minutes to read